Insulin-Treated T2D Patients Unwilling to Participate in Intensive Lifestyle Intervention
By Elana Gotkine HealthDay Reporter
MONDAY, June 10, 2024 -- For adults with advanced, insulin-treated type 2 diabetes (T2D), willingness to participate in an intensive lifestyle intervention (ILI) is very low, according to a research letter published online June 5 in Diabetes, Obesity and Metabolism.
Cathy J. Sun, M.D., from The Ottawa Hospital in Ontario, Canada, and colleagues designed an ILI pilot project for adults living with T2D, who were insulin-treated for at least five years, and with a body mass index of 27 to 45 kg/m2. The intervention was a 24-week ILI composed of three phases: four weeks of daily negative energy balance of 800 calories; four weeks of daily negative energy balance of 500 calories; and daily neutral energy balance for 16 weeks. Patients would have medication management monitoring and on-call privileges to the study's physician throughout the study.
The researchers found that 83 (15.0 percent) of the 555 patients screened met the inclusion criteria and were contacted by research assistants. Only two patients (0.4 percent) were potentially interested; one had extensive travel plans and the second subsequently did not want to participate. Eight-one patients refused to participate because the initial diet was too restrictive in daily calories, because the intervention was too demanding and would interfere with social life, and because of the requirement for multiple medication adjustments. The perception that the intervention was too intense was the main reason for refusal to participate.
"Optimal ways to approach and support patients with insulin-treated T2D for ILI remain to be established," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.